Prolonged response using gefitinib followed by sirolimus for advanced cutaneous squamous cell carcinoma.
Paolo
P
Bossi
Carlo
C
Resteghini
Federica
F
Perrone
Barbara
B
Cortelazzi
Silvana
S
Pilotti
Andrea
A
Maurichi
Laura D
LD
Locati
Lisa
L
Licitra
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D004359:Drug Therapy, Combination; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000077156:Gefitinib; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D011799:Quinazolines / Q000627:therapeutic use*; D020123:Sirolimus / Q000008:administration & dosage / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D012883:Skin Ulcer / Q000209:etiology; D058570:TOR Serine-Threonine Kinases / Q000235:genetics
D000970:Antineoplastic Agents; D011799:Quinazolines; C546842:MTOR protein, human; D066246:ErbB Receptors; D058570:TOR Serine-Threonine Kinases; D000077156:Gefitinib; D020123:Sirolimus